By Fineline Cube 
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has approved Adcetris (brentuximab vedotin), a CD30-targeted antibody-drug conjugate (ADC), in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (ECADD) for adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma.
BrECADD Regimen Approval
The EC approved the Adcetris-based combination regimen, known as BrECADD, for frontline Hodgkin lymphoma after reviewing positive results from the Phase III HD21 study. The trial met its co-primary endpoints of safety and efficacy, demonstrating that the BrECADD regimen offers improved safety while maintaining non-inferior progression-free survival (PFS) compared to the current European standard regimen, eBEACOPP.-Fineline Info & Tech